Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Kerr

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
The Lancet. Oncology|August 14, 2022
A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation studyAndreas Kleppe, Ole-Johan Skrede, Sepp De Raedt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2024
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled AnalysisBenoist Chibaudel, Morteza Raeisi, Romain Cohen, et al.
Clinical Colorectal Cancer|March 26, 2023
SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS)Mark P Saunders, Rohan Iype, Caroline Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2020
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant TrialsRomain Cohen, Julien Taieb, Jack Fiskum, et al.
Cell Reports. Medicine|September 18, 2024
Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancerMarta Nowak, Faiz Jabbar, Ann-Katrin Rodewald, et al.
Lancet (London, England)|February 3, 2020
Deep learning for prediction of colorectal cancer outcome: a discovery and validation studyOle-Johan Skrede, Sepp De Raedt, Andreas Kleppe, et al.
The Lancet. Oncology|June 22, 2014
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trialSusan J Dutton, David R Ferry, Jane M Blazeby, et al.
Journal of the National Cancer Institute|September 10, 2021
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer TrialsJun Yin, Mohamed E Salem, Jesse G Dixon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal CancerTimothy J Iveson, Alberto F Sobrero, Takayuki Yoshino, et al.
The Journal of Pathology|June 23, 2025
Analysis of IDH1 and IDH2 mutations as causes of the hypermethylator phenotype in colorectal cancerJoseph C Ward, Melissa Morgan, James Wood, et al.
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
The Lancet. Oncology|August 14, 2022
A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation studyAndreas Kleppe, Ole-Johan Skrede, Sepp De Raedt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2024
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled AnalysisBenoist Chibaudel, Morteza Raeisi, Romain Cohen, et al.
Clinical Colorectal Cancer|March 26, 2023
SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS)Mark P Saunders, Rohan Iype, Caroline Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2020
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant TrialsRomain Cohen, Julien Taieb, Jack Fiskum, et al.
Cell Reports. Medicine|September 18, 2024
Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancerMarta Nowak, Faiz Jabbar, Ann-Katrin Rodewald, et al.
Lancet (London, England)|February 3, 2020
Deep learning for prediction of colorectal cancer outcome: a discovery and validation studyOle-Johan Skrede, Sepp De Raedt, Andreas Kleppe, et al.
The Lancet. Oncology|June 22, 2014
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trialSusan J Dutton, David R Ferry, Jane M Blazeby, et al.
Journal of the National Cancer Institute|September 10, 2021
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer TrialsJun Yin, Mohamed E Salem, Jesse G Dixon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal CancerTimothy J Iveson, Alberto F Sobrero, Takayuki Yoshino, et al.
The Journal of Pathology|June 23, 2025
Analysis of IDH1 and IDH2 mutations as causes of the hypermethylator phenotype in colorectal cancerJoseph C Ward, Melissa Morgan, James Wood, et al.
Pageof 6